HRP20040974A2 - Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one - Google Patents

Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one

Info

Publication number
HRP20040974A2
HRP20040974A2 HR20040974A HRP20040974A HRP20040974A2 HR P20040974 A2 HRP20040974 A2 HR P20040974A2 HR 20040974 A HR20040974 A HR 20040974A HR P20040974 A HRP20040974 A HR P20040974A HR P20040974 A2 HRP20040974 A2 HR P20040974A2
Authority
HR
Croatia
Prior art keywords
compound
formula
image
fluorophenyl
trifluoromethyl
Prior art date
Application number
HR20040974A
Other languages
English (en)
Croatian (hr)
Inventor
Huffman Mark
Kaba Mahmoud
Joseph Payack F.
Hands David
Original Assignee
Merck & Co. Inc. Merck Sharp & Dohme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. Merck Sharp & Dohme Limited filed Critical Merck & Co. Inc. Merck Sharp & Dohme Limited
Publication of HRP20040974A2 publication Critical patent/HRP20040974A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HR20040974A 2002-04-18 2004-10-15 Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one HRP20040974A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37373402P 2002-04-18 2002-04-18
PCT/US2003/011956 WO2003089429A1 (en) 2002-04-18 2003-04-17 Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one

Publications (1)

Publication Number Publication Date
HRP20040974A2 true HRP20040974A2 (en) 2005-06-30

Family

ID=29251070

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040974A HRP20040974A2 (en) 2002-04-18 2004-10-15 Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one

Country Status (21)

Country Link
US (1) US7847095B2 (es)
EP (1) EP1499611B1 (es)
JP (1) JP4271586B2 (es)
KR (1) KR100982901B1 (es)
CN (1) CN1293077C (es)
AR (1) AR039625A1 (es)
AU (1) AU2003228578B2 (es)
BR (1) BR0309277A (es)
CA (1) CA2482466C (es)
EG (1) EG24127A (es)
HR (1) HRP20040974A2 (es)
IL (1) IL164586A (es)
MX (1) MXPA04010182A (es)
NO (1) NO330362B1 (es)
NZ (1) NZ535883A (es)
PL (1) PL217076B1 (es)
RU (1) RU2326879C2 (es)
TW (1) TWI341313B (es)
UA (1) UA84399C2 (es)
WO (1) WO2003089429A1 (es)
ZA (1) ZA200408193B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US8080656B2 (en) 2005-10-05 2011-12-20 Ranbaxy Laboratories Limited Process for the preparation of aprepitant
EP1942734A4 (en) * 2005-10-06 2010-04-07 Reddys Lab Ltd Dr PREPARATION OF THE APREPITANT
US9227958B2 (en) 2006-02-03 2016-01-05 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
EP2057151A4 (en) * 2006-08-28 2010-07-21 Hetero Drugs Ltd PROCESS FOR PURIFYING APREPITANT
US8940890B2 (en) 2010-05-24 2015-01-27 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Preparation method of 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl) phenyl]ethoxy]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
CN103030668B (zh) * 2011-10-09 2016-06-15 江苏豪森药业集团有限公司 一种制备福沙匹坦二甲葡胺的方法
EP2817305B1 (en) * 2012-02-23 2016-09-28 Piramal Enterprises Limited An improved process for the preparation of aprepitant
CZ304770B6 (cs) * 2012-03-13 2014-10-08 Zentiva, K.S. Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II
ITMI20130273A1 (it) * 2013-02-26 2014-08-27 Olon Spa Procedimento per la preparazione di aprepitant
CN103288813A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种阿瑞匹坦的制备方法
CN107954998B (zh) * 2016-10-14 2022-08-12 江苏豪森药业集团有限公司 福沙匹坦中间体的制备方法
CN106967057A (zh) * 2017-06-01 2017-07-21 四川制药制剂有限公司 一种阿瑞匹坦高效制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
GB9813025D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis

Also Published As

Publication number Publication date
JP4271586B2 (ja) 2009-06-03
EP1499611A4 (en) 2006-05-03
PL373348A1 (en) 2005-08-22
NZ535883A (en) 2007-12-21
EP1499611A1 (en) 2005-01-26
AR039625A1 (es) 2005-03-02
NO20045001L (no) 2004-11-17
WO2003089429A1 (en) 2003-10-30
KR20050007299A (ko) 2005-01-17
MXPA04010182A (es) 2005-02-03
US20050215786A1 (en) 2005-09-29
EG24127A (en) 2008-07-08
KR100982901B1 (ko) 2010-09-20
US7847095B2 (en) 2010-12-07
CA2482466C (en) 2012-11-20
IL164586A0 (en) 2005-12-18
BR0309277A (pt) 2005-02-22
JP2005529881A (ja) 2005-10-06
RU2004133678A (ru) 2005-05-27
TWI341313B (en) 2011-05-01
NO330362B1 (no) 2011-04-04
CN1293077C (zh) 2007-01-03
PL217076B1 (pl) 2014-06-30
EP1499611B1 (en) 2015-02-11
AU2003228578A1 (en) 2003-11-03
RU2326879C2 (ru) 2008-06-20
TW200400189A (en) 2004-01-01
UA84399C2 (en) 2008-10-27
IL164586A (en) 2010-11-30
ZA200408193B (en) 2006-06-28
CA2482466A1 (en) 2003-10-30
CN1646525A (zh) 2005-07-27
AU2003228578B2 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
HRP20040974A2 (en) Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one
EP2771004B1 (en) Inhibitors of the renal outer medullary potassium channel
KR101373902B1 (ko) 신장 바깥 수질 포타슘 채널의 억제제
TWI460166B (zh) 製備2-亞胺基-四氫噻唑-4-酮衍生物之新穎方法
EP2599781A1 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
JP2019194191A (ja) ビロキサジン塩を製造する方法及びその新規な多形
CA2961984A1 (en) Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
TWI225055B (en) Process for the preparation of 5-substituted isobenzofurans
US20030187274A1 (en) Process for the preparation of 1,2,4- triazolin-5-one derivatives
JP2022535112A (ja) 4-フェニル-5-アルコキシカルボニル-2-チアゾール-2-イル-1,4-ジヒドロピリミジン-6-イル]メチル]-3-オキソ-5,6,8,8a-テトラヒドロ-1H-イミダゾ[1,5-a]ピラジン-2-イル]-カルボン酸を調製するための代替方法
US20020016458A1 (en) Intramolecular glycosidation process for the synthesis of (2R, 2-alpha-R, 3A)-2-[1-(3,5- BIS (trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
KR100986734B1 (ko) 모사프리드 제조용 중간체의 제조방법
GB2281297A (en) Quinazoline compounds
JP2002356480A (ja) トランス−(5r)−2,4,5−トリ置換2−オキサゾリンの製造方法
JPH04270272A (ja) アミノアルキルモルホリン誘導体の製造法
JP3573364B2 (ja) 新規なn−(2−シンナミルアミノエチル)ナフタレンスルフォンアミド誘導体
EA046640B1 (ru) Способ и промежуточное соединение для получения оксетан-2-илметанамина
JP2005350390A (ja) 3−アミノフラボン化合物の製造方法
JPH07247275A (ja) オキサゾリジノン誘導体の単一のジアステレオマーの製造方法及びウレタン化合物の単一のジアステレオマーのフマル酸塩
JPH0748367A (ja) ビシクロアミン誘導体
JP2000191650A (ja) オキサゾリジノン誘導体の製法
NO171213B (no) Pyrazolo(1,5-a)pyrimidiner, saerlig egnet for anvendelse som mellomprodukt

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

Owner name: SCHERING CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20140410

Year of fee payment: 12

OBST Application withdrawn